Compare Amplify Cybersecurity ETF (HACK) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amplify Cybersecurity ETF vs State Street SPDR S&P Biotech ETF — how do they compare? Amplify Cybersecurity ETF trades at $125.61 (market cap $3.55B), while State Street SPDR S&P Biotech ETF trades at $149.81 (market cap $10.08B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 2.8× Amplify Cybersecurity ETF's market cap, and Amplify Cybersecurity ETF is trading nearer its 52-week high, State Street SPDR S&P Biotech ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Amplify Cybersecurity ETF for 30 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| HACK | XBI | |
|---|---|---|
Market Cap | $3.55B | $10.08B |
Volume | 233,961 | 9,534,635 |
Sector | Sector/Thematic | Broad Market / Factor |
52-Week High | $127.66 | $169.55 |
52-Week Low | $70.69 | $104.99 |
Typical Hold Time | 30 Days | 37 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HACK trades at $125.81, down 1.45% today but near its 52-week high, with a strong technical outlook showing bullish moving averages and key support at $124. Recent news highlights the ETF's momentum, driven by AI safety concerns and cybersecurity demand, with the fund up 84.96% from its 52-week low. Financial ratios are not disclosed for this ETF, but sector growth remains a tailwind.
The outlook for HACK is positive, supported by rising cybersecurity spending and AI-driven threats, though risks include increased short interest and sector volatility. Analyst sentiment is bullish, with the ETF positioned to benefit from ongoing digital security trends, but investors should monitor competitive and macroeconomic pressures.
XBI trades at $150.23, down 0.44% on the day, with bearish technical signals dominating. The ETF faces resistance near $152-154 while finding support at $147-149 levels. Analyst coverage remains limited with a single hold rating, though recent news highlights biotech sector optimism from M&A activity and cancer vaccine breakthroughs. The fund's 0.35% expense ratio compares unfavorably to broader healthcare ETFs but offers targeted biotech exposure.
Outlook remains mixed with technical weakness offset by sector catalysts. The biotech focus provides growth potential but carries higher volatility than diversified healthcare alternatives. Key risks include sector-specific regulatory pressures and the fund's expense structure, while opportunities exist from ongoing pharmaceutical innovation and capital market improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Amplify Cybersecurity ETF
HACK provides diversified exposure to the global cybersecurity industry. It invests across the full value chain, including hardware, software, and consulting services, with key holdings in firms like Broadcom, Cisco, and Palo Alto Networks.
Read more on HACK →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
